Journal article
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Abstract
BACKGROUND: The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.
PATIENTS AND METHODS: We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) with the same combination and epirubicin (TEC; 75 …
Authors
Lindemann K; Christensen RD; Vergote I; Stuart G; Izquierdo MA; Kærn J; Havsteen H; Eisenhauer E; Ridderheim M; Lopez AB
Journal
Annals of Oncology, Vol. 23, No. 10, pp. 2613–2619
Publisher
Elsevier
Publication Date
10 2012
DOI
10.1093/annonc/mds060
ISSN
0923-7534